Free Trial

argenex (ARGX) Stock Price, News & Analysis

argenex logo
$661.26 -2.47 (-0.37%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About argenex Stock (NASDAQ:ARGX)

Key Stats

Today's Range
$660.09
$671.66
50-Day Range
$537.92
$690.32
52-Week Range
$510.05
$696.21
Volume
154,400 shs
Average Volume
373,683 shs
Market Capitalization
$40.47 billion
P/E Ratio
33.91
Dividend Yield
N/A
Price Target
$746.81
Consensus Rating
Buy

Company Overview

argenex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

ARGX MarketRank™: 

argenex scored higher than 78% of companies evaluated by MarketBeat, and ranked 239th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    argenex has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 18 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    argenex has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about argenex's stock forecast and price target.
  • Earnings Growth

    Earnings for argenex are expected to grow by 246.65% in the coming year, from $3.13 to $10.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of argenex is 33.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.38.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of argenex is 33.99, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.90.

  • Price to Earnings Growth Ratio

    argenex has a PEG Ratio of 0.76. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    argenex has a P/B Ratio of 6.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about argenex's valuation and earnings.
  • Percentage of Shares Shorted

    3.15% of the float of argenex has been sold short.
  • Short Interest Ratio / Days to Cover

    argenex has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in argenex has recently increased by 4.44%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    argenex does not currently pay a dividend.

  • Dividend Growth

    argenex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.15% of the float of argenex has been sold short.
  • Short Interest Ratio / Days to Cover

    argenex has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in argenex has recently increased by 4.44%, indicating that investor sentiment is decreasing.
  • News Sentiment

    argenex has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for argenex this week, compared to 12 articles on an average week.
  • Search Interest

    15 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added argenex to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, argenex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.43% of the stock of argenex is held by insiders.

  • Percentage Held by Institutions

    60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about argenex's insider trading history.
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenex and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
See More Headlines

ARGX Stock Analysis - Frequently Asked Questions

argenex's stock was trading at $615.00 at the beginning of 2025. Since then, ARGX shares have increased by 7.5% and is now trading at $660.8950.

argenex SE (NASDAQ:ARGX) issued its earnings results on Thursday, July, 31st. The company reported $3.74 EPS for the quarter, topping the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million for the quarter, compared to analysts' expectations of $776.82 million. argenex had a net margin of 40.98% and a trailing twelve-month return on equity of 21.06%.
Read the conference call transcript
.

argenex (ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Top institutional shareholders of argenex include Artisan Partners Limited Partnership (3.84%), Bellevue Group AG (0.93%), Bank of America Corp DE (0.55%) and Sei Investments Co. (0.52%).

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that argenex investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

Last Earnings
7/31/2025
Today
8/22/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARGX
CIK
1697862
Fax
N/A
Employees
1,599
Year Founded
2008

Price Target and Rating

High Price Target
$1,070.00
Low Price Target
$605.00
Potential Upside/Downside
+12.5%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
20 Analysts

Profitability

EPS (Trailing Twelve Months)
$19.50
Trailing P/E Ratio
34.04
Forward P/E Ratio
212.05
P/E Growth
0.76
Net Income
$833.04 million
Net Margins
40.98%
Pretax Margin
21.24%
Return on Equity
21.06%
Return on Assets
18.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.60
Quick Ratio
5.27

Sales & Book Value

Annual Sales
$3.05 billion
Price / Sales
13.31
Cash Flow
$2.98 per share
Price / Cash Flow
222.51
Book Value
$99.60 per share
Price / Book
6.66

Miscellaneous

Outstanding Shares
61,200,000
Free Float
59,713,000
Market Cap
$40.62 billion
Optionable
Optionable
Beta
0.39

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ARGX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners